13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001986035
Total reported value
—
$233.6M
30 檔
50.2%
As reported in its official Q1 2024 Form 13F filing, Altitude Crest Partners Inc.'s tracked investment portfolio stood at $233.6M with 30 total positions.
During Q1 2024, Altitude Crest Partners Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LEGN | Legend Biotech Corp-adr | Stock-Other | 15.67% | — | +20.47% | |
| 2 | DHR | Danaher CORP | Stock-Healthcare | 11.62% | — | -10.61% | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 8.10% | — | -18.89% | |
| 4 | STVN | Stevanato Group S.p.A. | Stock-Other | 7.56% | — | — | |
| 5 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 7.23% | — | +88.75% | |
| 6 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 4.58% | — | — | |
| 7 | AVBP | Arrivent Biopharma Inc | Stock-Other | 4.25% | — | — | |
| 8 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.76% | — | — | |
| 9 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 3.38% | — | -12.19% | |
| 10 | JANX | Janux Therapeutics Inc | Stock-Other | 3.12% | — | — | |
| 11 | LLY | Eli Lilly & Co | Stock-Healthcare | 3.06% | — | — | |
| 12 | BHVN | Biohaven Ltd. | Stock-Other | 2.77% | — | — | |
| 13 | IMNM | Immunome Inc | Stock-Other | 2.77% | — | — | |
| 14 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 2.71% | — | — | |
| 15 | GERN | Geron CORP | Stock-Other | 2.16% | — | — | |
| 16 | ICLR | ICON Public Limited Company | Stock-Healthcare | 2.13% | — | — | |
| 17 | ✓ | Merus N V | Stock-Other | 2.12% | — | — | |
| 18 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 2.05% | — | -43.72% | |
| 19 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.84% | — | — | |
| 20 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.74% | — | — | |
| 21 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.42% | — | — | |
| 22 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.38% | — | — | |
| 23 | ✓ | Aligos Therapeutics Inc | Stock-Other | 1.19% | — | — | |
| 24 | ✓ | Engene Holdings Inc | Stock-Other | 0.87% | — | — | |
| 25 | APLT | Applied Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 26 | ZYME | Zymeworks Inc | Stock-Other | 0.66% | — | — | |
| 27 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 0.60% | — | — | |
| 28 | TRML | Tourmaline Bio Inc | Stock-Other | 0.46% | — | — | |
| 29 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.01% | — | — | |
| 30 | SRZNW | Surrozen Inc-cw25 | Stock-Other | 0.01% | — | — |
According to official SEC Form 13F filings, Altitude Crest Partners Inc. reported a total U.S. public equity portfolio value of $233.6M across 30 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LEGN, DHR, BBIO) accounted for 50.2% of total reported equity market value during Q1 2024.
During Q1 2024, Altitude Crest Partners Inc.'s top holdings by market value included LEGN (15.7%)、DHR (11.6%)、BBIO (8.1%). The largest single position, LEGN, represented 15.7% of total portfolio value.
In Q1 2024, Altitude Crest Partners Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.